Lithium Reactions 1680, p207 - 2 Dec 2017 Neurotoxicity: 2 case reports A 54-year-old man and a 76-year-old man developed lithium neurotoxicity [routes and time to reactions onsets not stated]. A 76-year-old man, who had bipolar I disorder, started receiving therapy with lithium 300mg twice daily. He was hospitalised with a diagnosis of mixed manic-depressive disorder. At the time of admission, he was confused and experienced balancing difficulty. A total work up of delirium showed no clear cause. Following a neurological consultation, diagnosis of delirium was agreed upon, and lithium neurotoxicity was suggested despite of normal lithium therapeutic level of 0.71 (lithium therapeutic range: 0.6-1.2). Later on, his delirium improved and eventually resolved after lithium withdrawal. A 54-year-old man, who had schizophrenia, started receiving therapy with lithium 300mg twice daily and clozapine. Later, he presented with recurrent falls related to postural instability. His lithium level was 0.6 (lithium therapeutic range: 0.6-1.2). Diagnosis of lithium neurotoxicity was made with lithium being within therapeutic levels. His motor difficulties recovered after discontinuation of lithium treatment. Author comment: "Because lithium neurotoxicity may occur with therapeutic serum levels, and may occasionally be irreversible, lithium should be discontinued until it is clear that it is not contributing to the neurological dysfunction." "We present two cases of lithium neurotoxicity within therapeutic lithium levels." Moustafa Y, et al. Lithium-induced neurotoxicity at therapeutic levels: Illustrative cases and literature review. CNS Spectrums 22: 104-105, No. 1, Feb 2017. Available from: URL: [abstract] - USA 803284752 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial